BioSpace News Archive

LianBio today announced the appointment of Jesse Wu to the company’s Board of Directors.

New Real-World MAVENCLAD ® Data Show Sustained Effectiveness and Benefit on Quality-of-Life Measures in RMS Patients

Subtle Medical, a healthcare technology company improving the quality and efficiency of medical imaging, announced today Health Canada/Santé Canada approval for their suite of AI-powered image enhancement solutions.

Foundation Medicine, Inc. today announced the appointment of Dymeka Harrison, MBA, as its Chief Commercial Officer.

LEXEO Therapeutics and FUJIFILM Diosynth Biotechnologies today announced a strategic collaboration to support the development and manufacturing of LEXEO’s AAV-mediated gene therapies.

Abeona Therapeutics Inc. today announced two presentations of previously disclosed clinical data at upcoming scientific congresses in October 2021.

Alnylam Pharmaceuticals, Inc. today announced the launch of Alnylam Challengers, a signature community impact program that will support bold and diverse organizations in their pursuit of developing new and sustainable solutions to address challenges in health equity.

Apnimed today announced positive data across multiple endpoints from a Phase 2 randomized, double-blind, placebo-controlled, four-period, single-dose crossover factorial clinical trial (APC-003), and a 28-day open-label extension study, evaluating AD109 as a treatment in patients with mild to severe OSA.

Resverlogix Corp., a world leader in epigenetics or gene regulation, announces that President and CEO Donald McCaffrey will be presenting virtually at the following conferences.

TRACON Pharmaceuticals, a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and utilizing a product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., announced the appointment of Carol Lam to its Board of Directors.